Seres Therapeutics, Inc. (MCRB)
- Business Wire
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
- Business Wire
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CAMBRIDGE, Mass., April 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting b
- Simply Wall St.
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
Key Insights Seres Therapeutics' Annual General Meeting to take place on 4th of April CEO Eric Shaff's total...
